ArticleDrugs & aging2014
Adverse drug reactions in elderly subjects hospitalized in a specialized dementia management unit.
Article in Drugs & aging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 26 citations in OpenAlex.
- Effect of pharmacist-led medication reviews on appropriateness of prescribing in patients with dementia - results from the cluster randomized controlled "DemStepCare" study.BMC geriatrics · 2025Trial
- Exploring current approaches towards patient prioritisation for clinical pharmacy services in UK mental health inpatient care.BMC psychiatry · 2025Article
- No impact of a prescription booklet on medication consumption in nursing home residents from 2011 to 2014: a controlled before-after study.Aging clinical and experimental research · 2021Article
- An examination of three prescribing cascades in a cohort of older adults with dementia.BMC geriatrics · 2021Article
- Potentially inappropriate prescribing in dementia: a state-of-the-art review since 2007.BMJ open · 2020Review
- Prevalence of and risk factors for adverse events in Alzheimer's patients receiving anti-dementia drugs in at-home care.PloS one · 2020Article
- Use of Anti-Dementia Drugs Reduces the Risk of Potentially Inappropriate Medications: A Secondary Analysis of a Nationwide Survey of Prescribing Pharmacies.Dementia and geriatric cognitive disorders · 2020Article
- Adverse Drug Events in Patients with Dementia and Neuropsychiatric/Behavioral, and Psychological Symptoms, a One-Year Prospective Study.International journal of environmental research and public health · 2019Article
- Influence of pharmacist intervention on drug safety of geriatric inpatients: a prospective, controlled trial.Therapeutic advances in drug safety · 2019Article
- Drug-drug interactions involving antidepressants: focus on desvenlafaxine.Neuropsychiatric disease and treatment · 2018Review
- A Pharmacist-Physician Intervention Model Using a Computerized Alert System to Reduce High-Risk Medication Use in Elderly Inpatients.Drugs & aging · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDrug prescriptions represent an actionable item in the prevention of adverse drug reactions (ADRs). The aims of this study were to identify risk factors for the occurrence of ADRs, and to describe symptoms and drug interactions.
methodsThis was a longitudinal study over a period of 19 months in an acute geriatric ward specializing in the management of dementia. Independent risk factors for ADRs were identified by logistic regression. Drug interactions were also recorded.
resultsIn total, 293 patients were included (age 82 ± 8 years). The prevalence of ADRs was 24 %. Patients were taking 8 ± 3 drugs per day; 72 (24.6 %) were taking more than three psychotropics. The main therapeutic classes prescribed were anxiolytics and hypnotics (57.7 %), antidementia drugs (54.6 %), antidepressants (54.3 %), antithrombotics (54.0 %), angiotensin-converting enzyme inhibitors [ACEIs] or angiotensin II receptor blockers [ARBs] (37.5 %). The risk of ADRs was significantly higher in patients taking neuroleptics (odds ratio [OR] 2.04; 95 % confidence interval [CI] 1.06-3.92), ACEIs/ARBs (OR 2.07; 95 % CI 1.13-3.77) and antidementia drugs (OR 1.84; 95 % CI 1.01-3.36). The risk of serious ADRs was significantly higher in patients taking ACEIs/ARBs (OR 2.95; 95 % CI 1.40-6.21), type I, III or IV antiarrhythmics (OR 2.71; 95 % CI 1.07-6.88) or neuroleptics (OR 2.42; 95 % CI 1.09-5.40). Drug interactions were involved in 26.3 % (n = 21) of ADRs; the combination of an ADR plus a drug interaction was associated with increased severity (p = 0.02).
conclusionCaution is needed when prescribing ACEIs/ARBs, neuroleptics, antidementia drugs, or certain types of antiarrhythmics in patients suffering from dementia. Psychotropics should be avoided because of the associated risk of ADRs and drug interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.